Lentiviral Transduction of Organoids: 4 Strategies to Improve Efficiency

Organoids are widely recognized as challenging in vitro models for gene delivery and viral transduction, largely because of their dense three-dimensional (3D) architecture and tight cell-cell junctions.

Most organoids are embedded in extracellular matrix (ECM) hydrogels such as basement membrane matrix. Before reaching the cells, viral particles must first penetrate this surrounding matrix. Even after crossing the matrix barrier, viruses may have difficulty reaching cells located deep within the organoid because of the extracellular matrix and tight intercellular junctions. As a result, viral transduction is often restricted to the outer cell layers, while cells in the organoid core remain largely untransduced.

This outer-transduced, core-untransduced pattern is one of the most common failure modes in organoid transduction.

To address this challenge, four practical strategies can be considered.

Strategy 1: Physical Reconstruction —— Dissociate the Organoid into Single Cells Before Lentiviral Transduction

For densely structured organoids, such as brain organoids and solid tumor organoids, physical reconstruction can be one of the most effective approaches.

The basic workflow is to gently dissociate the organoid into a single-cell suspension, incubate the cells with lentiviral vectors in the dissociated state, and then re-embed the transduced cells in an appropriate extracellular matrix for 3D reconstruction and culture.

The major advantage of this approach is its high and relatively uniform transduction efficiency, which can approach 100% under optimized experimental conditions. However, dissociation also disrupts the original cell-cell interactions and self-organizing signals within the organoid.

Therefore, this strategy is particularly suitable for establishing stable genetically modified organoid lines, but may be less appropriate for studies that focus on short-term cellular rearrangement, polarity restoration, or other processes that depend on the intact organoid architecture following viral transduction.

Figure 1. Schematic illustration of organoid infection using the physical reconstruction approach. [PMID: 27246018]

Strategy 2: Parameter Titration —— Optimize MOI and Use Transduction Enhancers When Appropriate

When maintaining the intact 3D structure of the organoid is essential, systematic MOI (multiplicity of infection) optimization is critical.

Different organoid models can vary substantially in their tolerance to viral vectors and their optimal transduction window. Before conducting the main experiment, it is therefore recommended to perform an MOI titration experiment using a fluorescent reporter lentiviral vector, such as GFP lentivirus.

This preliminary experiment can help identify an appropriate viral dose that provides sufficient transduction while minimizing cytotoxicity.

Transduction-enhancing reagents can also be used when appropriate. These reagents can reduce electrostatic repulsion between viral particles and cell membranes, thereby improving viral entry into cells, particularly those located in the outer layers of the organoid.

However, Polybrene may exhibit cytotoxic effects in certain organoid models. A preliminary dose-response experiment should therefore be performed to determine a suitable concentration before large-scale experiments.

Strategy 3: Barrier-Breaking Approaches —— Microinjection and Viral Pseudotyping

Tubular or lumen-containing organoids, including intestinal and airway organoids, present an additional challenge because they often exhibit pronounced cellular polarity or are surrounded by a mucus barrier.

In these models, the apical surface of epithelial cells faces the lumen, while the basolateral surface faces the surrounding extracellular matrix. Viral receptors may be preferentially localized to the basolateral surface. Consequently, viruses added externally may have limited access to their target receptors, resulting in poor transduction efficiency.

Two approaches can be considered in this situation: microinjection and viral envelope modification/pseudotyping.

Microinjection

Microinjection can be used to deliver viral vectors directly into the lumen of an organoid, allowing the virus to reach target cells from the apical side.

This approach can reduce the amount of viral vector required and potentially minimize cytotoxicity while preserving the overall organoid architecture.

When combined with cell- or tissue-specific promoters, microinjection can also facilitate more precise targeting of specific regions within an organoid. For example, targeted viral delivery has been used in specific regions of midbrain organoids, including tube-like ventricular zone (VZ) regions.

Viral Pseudotyping

Another approach is to select or engineer viral vectors with envelopes that have appropriate receptor recognition properties.

For lentiviral vectors, envelopes such as VSV-G, RD114, and BaEV can be considered depending on the target cell type and experimental requirements. Appropriate pseudotyping may improve viral attachment and entry into specific cell populations and help overcome barriers associated with cellular polarity or mucus.

This strategy is commonly considered when the goal is to achieve more selective lentiviral transduction of specific cells or tissues within organoid models.

Strategy 4: Repeated Transduction —— Pulse-Based Repeated Transduction

For organoid models that are particularly resistant to viral transduction or exhibit relatively slow proliferation—such as certain liver organoids and organoids derived from normal tissues—a single round of infection may not produce a sufficient proportion of transduced cells.

In these cases, a repeated transduction strategy can be considered.

Following organoid passaging, lentiviral transduction can be performed in a pulse-based manner over 2–3 consecutive days, with fresh culture medium provided after each transduction cycle.

The goal is to increase the cumulative proportion of transduced cells by providing multiple opportunities for viral entry.

The key to this approach is careful control of the viral dose and exposure time during each round of transduction. Excessive viral exposure may increase cumulative cytotoxicity and compromise organoid viability.

Combining Multiple Strategies for Better Organoid Transduction

In practice, these four strategies do not necessarily need to be used independently. Combining different approaches according to the characteristics of the organoid model may provide better results.

For example, when performing gene editing in intestinal organoids, researchers may first dissociate the organoids into single cells for lentiviral transduction, followed by selection of positive clones and 3D reconstruction. During the expansion stage, MOI optimization can be used to maintain relatively uniform transduction.

The optimal lentiviral transduction strategy for organoids varies considerably depending on the organoid type, cellular composition, structural characteristics, viral vector, and experimental objective. Therefore, experimental parameters should be optimized for the specific organoid model rather than applying a single universal protocol.

In the next article, we will examine specific publications and customer case studies to explore how lentiviral vectors and organoid models are being applied in cancer research, precision medicine, and drug screening.

References

1. Maru Y, Orihashi K, Hippo Y. Lentivirus-Based Stable Gene Delivery into Intestinal Organoids. Methods Mol Biol. 2016;1422:13–21. doi: 10.1007/978-1-4939-3603-8_2.
2. Tao M, Chen Q, Gao W, Wu S, Liu Y. Protocol for differentiating human pluripotent stem cells into midbrain organoids for targeted microinjection of viruses. STAR Protoc. 2025 Sep 19;6(3):103983. doi: 10.1016/j.xpro.2025.103983.
3. Walczak F, Szymkiewicz A, Pacak I, Kowalik A. Autotransduction and Pseudotyping as a Key Limitations in Lentiviral Vector Production. Biotechnol J. 2026 Apr;21(4):e70219. doi: 10.1002/biot.70219.

OBiO Tech Support for Organoid Transduction

To address the technical challenges associated with lentiviral transduction of organoids, OBiO Tech provides an integrated workflow covering vector construction and lentiviral packaging.

Our proprietary Vpack high-titer packaging system enables lentiviral titers of10⁸–10⁹ TU/mL, providing sufficient viral input for organoid models with different requirements for viral dose and transduction efficiency.

Depending on the experimental objective, researchers can also select lentiviral vectors with different envelope types to better accommodate organoids derived from different tissues and cell types.

The service covers the complete workflow from vector construction to lentiviralpackaging, enabling streamlined delivery of customized lentiviral vectors for organoid research.

For additional technical parameters or experimental condition references, researchers can contact the OBiO Tech technical support team for tailored guidance.